APA (7th ed.) Citation

Hitchen, N., Waldron, N. R., Deva, S., Findlay, M., & Lawrence, B. (2023). Real‐world outcomes of cisplatin, capecitabine, and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first‐line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma. Asia Pacific Journal of Clinical Oncology, 19(5), e231. https://doi.org/10.1111/ajco.13845

Chicago Style (17th ed.) Citation

Hitchen, Nadia, Nick R. Waldron, Sanjeev Deva, Michael Findlay, and Benjamin Lawrence. "Real‐world Outcomes of Cisplatin, Capecitabine, and Gemcitabine with Either Epirubicin (PEXG) or Docetaxel (PDXG) as First‐line Palliative Treatment in Metastatic or Unresectable Locally Advanced Pancreatic Adenocarcinoma." Asia Pacific Journal of Clinical Oncology 19, no. 5 (2023): e231. https://doi.org/10.1111/ajco.13845.

MLA (9th ed.) Citation

Hitchen, Nadia, et al. "Real‐world Outcomes of Cisplatin, Capecitabine, and Gemcitabine with Either Epirubicin (PEXG) or Docetaxel (PDXG) as First‐line Palliative Treatment in Metastatic or Unresectable Locally Advanced Pancreatic Adenocarcinoma." Asia Pacific Journal of Clinical Oncology, vol. 19, no. 5, 2023, p. e231, https://doi.org/10.1111/ajco.13845.